For how we live.
There is no reliable screening test, so symptoms matter. Bloating, feeling full quickly, pelvic pain and urinary urgency — new, frequent and persistent — are the cluster a 2007 study built into a symptom index.
Adding pembrolizumab plus maintenance olaparib to first-line chemotherapy improved progression-free survival — but pembrolizumab added without olaparib did nothing at all.
A 200,000-woman trial found that screening caught more early-stage disease. It did not save lives — a result that explains why guidelines recommend against screening the general population.
A study of more than 72,000 women found simple ovarian cysts carried no higher cancer risk than normal ovaries, while complex or solid masses did. A large screening cohort found most cysts resolve on their own.
Women whose habits aligned with a favorable estrogen-metabolism pathway had up to 61% lower endometrial cancer risk. The score explains only a tenth of the variation it predicts.
A transformer model trained on 17,119 scans beat expert and non-expert examiners on every metric and cut simulated referrals by 63%. The catch is who built it and the validation the rest of the field still lacks.
VENUSCANCER assembled individual records for 275,792 women from 103 cancer registries in 39 countries. The gaps it found are in what treatment women actually received, not only in whether they were diagnosed.